AlphAIAlphAI — Financial news for AI agents
investing.comOCT 132 min read$PLSE

Oppenheimer raises Pulse Biosciences price target on competitor issues

Oppenheimer raised its price target for Pulse Biosciences (PLSE) to $60 from $35, citing competitor challenges. The stock trades at $52.45 with a $3.74B market cap. Analysts highlight a pivotal trial in 2027 and recent equity agreements. Multiple analysts initiated coverage with buy ratings and price targets ranging from $58 to $73.

Original reporting
investing.com
Published Oct 13, 2026, 10:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PLSE
Bullish
high confidence
Mentioned
$PLSE
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PLSEBullishMed
01

Why it matters

Analyst upgrades and a new equity distribution agreement could drive short‑term buying interest, but long‑term performance hinges on trial outcomes.

02

Market read

The news provides a fresh catalyst for PLSE, potentially prompting a price rally, while offering a data point for sector peers.

03

What to watch

Potential regulatory hurdles and competition from larger players like Johnson & Johnson could limit upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Pulse Biosciences develops nanosecond pulsed field ablation for atrial fibrillation; analysts are initiating coverage amid competitor setbacks.

Company-level read

Ticker impact

$PLSEBullishHigh confidence
Context

Oppenheimer raised its price target on Pulse Biosciences (PLSE) to $60 from $35, citing competitor challenges and a new $85 M equity distribution agreement.

Expected impact

likely upward pressure as investors price in the higher target and new capital raise.

Evidence & confidence

The price‑target hike reflects a bullish view; the distribution agreement provides liquidity and may attract additional investors, supporting a short‑term rally.

Market effects

Sector

Positive signal for the cardiac‑ablation biotech niche, may lift peer valuations.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to investors tracking emerging medical‑device technologies.

Counterpoint

What could challenge this read

The price target increase may be premature given the technology’s early stage and pending pivotal trial in 2027.

Key entities

  • company
    Pulse Biosciences

    Biotech firm developing pulsed field ablation technology.

  • analyst_firm
    Oppenheimer

    Raised price target on PLSE.

Read at source← All news

Related articles

OCT 8
$PLSEMedAI 8/10

How Trial Enrollment Completion At Pulse Biosciences (PLSE) Has Changed Its Investment Story

Pulse Biosciences (PLSE) completed enrollment for its NANOPULSE-AF study, meeting its target of 164 patients across 15 sites. The study aims to assess the safety and effectiveness of its nPulse Cardiac Catheter System for drug-resistant atrial fibrillation. Analysts forecast revenue of $38.3M and earnings of $4.8M by 2029, with significant growth and earnings swing expected. The trial's outcomes will influence regulatory, reimbursement, and commercialization decisions.

simplywall.st3 min
OCT 7
$PLSEMedAI 8/10

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation…

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse ™ Cardiac Catheter System for Atrial Fibrillation Treatment 164 evaluable patients enrolled across 15 clinical sites HAYWARD, California , October 7, 2026 — Puls

SEC EDGAR 8-K2 min
OCT 7
$PLSELowAI 8/10

Pulse Biosciences completes enrollment in cardiac ablation study

Pulse Biosciences (PLSE) completed enrollment in its NANOPULSE-AF Study for treating atrial fibrillation, hitting its 164-patient target three months early. The study evaluates the safety and effectiveness of its nPulse Cardiac Catheter System. Primary endpoints will be assessed at six and 12 months post-ablation. The company plans to share updates and present data at future conferences.

investing.com1 min
OCT 6
$PLSEMed

Canaccord raises Pulse Biosciences stock price target on tech potential

Canaccord raised its price target on Pulse Biosciences (PLSE) to $58 from $43, maintaining a Buy rating. The stock has surged 87.5% since Canaccord initiated coverage and 268% year-to-date, with a $3.6B market cap. The firm cited the company's nanosecond pulse field ablation platform and clinical progress. Pulse also announced an equity distribution agreement with Mizuho Securities for up to $85M in common stock sales.

investing.com2 min
SEP 15
$PLSEMedAI 8/10

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic…

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse ™ Vybrance ™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed

SEC EDGAR 8-K1 min